Bifogade filer
PM-Johan-Wieslander-exercises-warrants-Emplicure-AB.pdf
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Johan Wieslander, who is a board member of Emplicure AB (publ) ("Emplicure" or the "Company"), has acquired an additional 1,500,000 warrants of series TO1, in addition to the warrants previously held by him that have already been exercised for subscription of shares in the Company. Johan Wieslander has exercised the the additional 1,500,000 warrants for subscription of 1,500,000 shares in the Company, meaning that the Company receives approximately SEK 3.1 million.
Summarized terms for warrants of series TO1:
Last day of exercise of TO1 for subscription of shares: May 13, 2022.
Subscription price: SEK 2.09 per share.
Volume: 9,600,000 warrants of series TO1. If all warrants of series TO1 are exercised, the number of shares in the Company will increase with 9,600,00 shares, and the Company will receive approximately SEK 20.1 million before issuing costs.
Last day for trading with warrants of series TO1: May 11, 2022.
Advisors
Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.
For more information, please contact:
Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: torbjorn.walkerlarsson@emplicure.com
Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com
Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se
The following documents can be retrieved from beQuoted
PM-Johan-Wieslander-exercises-warrants-Emplicure-AB.pdf
Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with white tobacco-free nicotine pouches as the first product. Read more at www.emplicure.com